Understanding Drug Costs
The financial aspect of potent weight-loss medications, such as Mounjaro, is a significant consideration for many. Reports indicate that the monthly expenditure
for these drugs can range broadly, from approximately Rs 10,000 for lower dosages to as much as Rs 22,000 for higher strength prescriptions. Initially, pricing was often per injection, but current market trends suggest a monthly cost framework. Experts suggest that the price is influenced by pharmaceutical company investments in research and development, and as more companies enter the market with similar patented drugs, prices are anticipated to decrease over time. This dynamic pricing reflects the business models of drug manufacturers, balancing innovation costs with market accessibility.
Who Qualifies for Treatment
Eligibility for weight-loss drugs isn't based solely on a desire to shed a few pounds. Medical professionals recommend these treatments primarily for individuals managing significant health conditions where weight loss offers tangible benefits. This includes people with conditions like diabetes, pre-diabetes, or fatty liver disease, where excess weight exacerbates their existing health challenges. A person with a Body Mass Index (BMI) of 27 who also has associated health issues may be considered a candidate. Furthermore, individuals with a BMI exceeding 30, even without other health problems, are often deemed suitable. For those with a BMI of 40 or above, while these drugs can still be effective, medical professionals might also explore surgical options like bariatric procedures as a primary intervention.
Who Should Avoid Medication
It is paramount to understand that certain individuals are not suitable candidates for weight-loss medications due to potential adverse health implications. These drugs carry risks, and informed consent requires awareness of contraindications. Individuals with a personal or family history of thyroid cancer are strongly advised against using these medications. Similarly, those who have experienced pancreatitis should refrain from such treatments. Pre-existing gastrointestinal issues also represent a significant concern, as these drugs can potentially worsen such conditions. Furthermore, individuals with active eye diseases, particularly those linked to diabetes, must exercise extreme caution and likely avoid these medications. Consulting with a healthcare expert is essential to evaluate personal medical history and understand the specific risks before considering any weight-loss drug.
